These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 35129466)
1. An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE). Elliott JA; Markar SR; Klevebro F; Johar A; Goense L; Lagergren P; Zaninotto G; van Hillegersberg R; van Berge Henegouwen MI; Nilsson M; Hanna GB; Reynolds JV; Ann Surg; 2023 May; 277(5):e1035-e1044. PubMed ID: 35129466 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study. Elliott JA; Klevebro F; Mantziari S; Markar SR; Goense L; Johar A; Lagergren P; Zaninotto G; van Hillegersberg R; van Berge Henegouwen MI; Schäfer M; Nilsson M; Hanna GB; Reynolds JV; Ann Surg; 2023 Nov; 278(5):692-700. PubMed ID: 37470379 [TBL] [Abstract][Full Text] [Related]
3. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055 [TBL] [Abstract][Full Text] [Related]
4. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study. Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555 [TBL] [Abstract][Full Text] [Related]
5. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104 [TBL] [Abstract][Full Text] [Related]
6. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574 [TBL] [Abstract][Full Text] [Related]
7. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728 [TBL] [Abstract][Full Text] [Related]
8. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study. Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152 [TBL] [Abstract][Full Text] [Related]
9. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. van der Wilk BJ; Noordman BJ; Neijenhuis LKA; Nieboer D; Nieuwenhuijzen GAP; Sosef MN; van Berge Henegouwen MI; Lagarde SM; Spaander MCW; Valkema R; Biermann K; Wijnhoven BPL; van der Gaast A; van Lanschot JJB; Doukas M; Nikkessen S; Luyer M; Schoon EJ; Roef MJ; van Lijnschoten I; Oostenbrug LE; Riedl RG; Gisbertz SS; Krishnadath KK; Bennink RJ; Meijer SL; Ann Surg; 2021 Dec; 274(6):1009-1016. PubMed ID: 31592898 [TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in recurrent esophageal or junctional cancer. Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371 [TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrent disease after neoadjuvant chemoradiotherapy and esophageal cancer surgery with curative intent in a tertiary referral center. Schuring N; Stam WT; Plat VD; Kalff MC; Hulshof MCCM; van Laarhoven HWM; Derks S; van der Peet DL; van Berge Henegouwen MI; Daams F; Gisbertz SS Eur J Surg Oncol; 2023 Oct; 49(10):106947. PubMed ID: 37355392 [TBL] [Abstract][Full Text] [Related]
13. Oncological recurrence following pathological complete response after neoadjuvant treatment in patients with esophageal cancer - a retrospective cohort study. Hipp J; Kuvendjiska J; Hillebrecht HC; Herrmann S; Timme-Bronsert S; Fichtner-Feigl S; Hoeppner J; Diener MK Langenbecks Arch Surg; 2023 Sep; 408(1):363. PubMed ID: 37721586 [TBL] [Abstract][Full Text] [Related]
14. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study. Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805 [TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. Mant D; Gray A; Pugh S; Campbell H; George S; Fuller A; Shinkins B; Corkhill A; Mellor J; Dixon E; Little L; Perera-Salazar R; Primrose J Health Technol Assess; 2017 May; 21(32):1-86. PubMed ID: 28641703 [TBL] [Abstract][Full Text] [Related]
16. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. Papaxoinis G; Kamposioras K; Weaver JMJ; Kordatou Z; Stamatopoulou S; Germetaki T; Nasralla M; Owen-Holt V; Anthoney A; Mansoor W J Gastrointest Surg; 2019 Sep; 23(9):1729-1741. PubMed ID: 30671799 [TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study. Schuring N; Markar SR; Hagens ERC; Jezerskyte E; Sprangers MAG; Lagergren P; Johar A; Gisbertz SS; van Berge Henegouwen MI; Dis Esophagus; 2023 Mar; 36(4):. PubMed ID: 36241253 [TBL] [Abstract][Full Text] [Related]
18. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2. van der Zijden CJ; Lagarde SM; Hermus M; Kranenburg LW; van Lanschot JJB; Mostert B; Nuyttens JJME; Oudijk L; van der Sluis PC; Spaander MCW; Valkema MJ; Valkema R; Wijnhoven BPL; BMC Cancer; 2023 Apr; 23(1):327. PubMed ID: 37038138 [TBL] [Abstract][Full Text] [Related]
19. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E Cancer Med; 2020 May; 9(9):3023-3032. PubMed ID: 32130793 [TBL] [Abstract][Full Text] [Related]
20. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]